At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 8 enrolled
Drug / intervention
QTI571drug
Likely dose
QTI571 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment
In Brief
A Phase 3 clinical trial evaluating QTI571 for Severe Pulmonary Arterial Hypertension. Completed, enrolled 8 participants across 3 sites.
Detailed Summary
To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSevere Pulmonary Arterial Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 2014
Enrollment StartJan 2014
Primary CompletionOct 2016
TodayJul 2026
First PostedJan 22, 2014
Enrollment StartJan 22, 2014
Primary CompletionOct 17, 2016
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.4 years ago
Interventions
QTI571drug
QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.